Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q2 FY26
Investor Presentation
Q2 FY25
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY22
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY22
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discovery themes featuring this stock
Beta Drugs Ltd (BETA) is currently trading at 1,328.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Beta Drugs Limited is primarily engaged in manufacturing and marketing oncology drug products, catering to both domestic and international markets. The company experienced a 13% revenue growth year-over-year, with notable expansions into 46+ countries, showcasing its extensive global reach and market acceptance. Beta Drugs Limited acquired an oncology intermediate facility to enhance backward integration, reducing dependency on imports and improving margins. Its entry into the cosmeceutical market through an exclusive agreement with Promoitalia marks a strategic diversification, enhancing their product offerings in high-end derma fillers. The company is positioned for growth, focusing on developing in-house API capabilities and expanding its CDMO business, reflecting strategic investments in R&D and production capacities.
Over the past 52 weeks, Beta Drugs Ltd has traded between a low of ₹990.10 and a high of ₹2,000.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Beta Drugs Ltd has a market capitalization of approximately 1,341.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Beta Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,341.82 Cr, Beta Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Beta Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Beta Drugs Ltd is 33.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2329.00 | 1,405 Cr | 40.99 | 4.68 | 0.08 | 6.89 | 8.00 | 7.25 | ||
926.00 | 1,405 Cr | 16.22 | 2.36 | 0.00 | 10.66 | 13.99 | 9.93 | ||
33.48 | 1,385 Cr | 50.73 | 126.56 | 0.03 | — | — | 0.00 | ||
528.80 | 1,382 Cr | 46.57 | 4.56 | 0.00 | 6.43 | 8.43 | 5.62 | ||
201.35 | 1,343 Cr | 33.20 | 5.31 | 1.24 | 17.30 | 21.58 | 13.68 | ||
1394.40 | 1,342 Cr | 33.18 | 5.88 | 0.00 | 18.96 | 18.07 | 8.50 | ||
14.04 | 1,294 Cr | 18.00 | 3.42 | 0.00 | 16.66 | 22.00 | 15.12 | ||
| Median: 7 Co. | — | 528.80 | 1,382 Cr | 33.20 | 4.68 | 0.00 | 13.66 | 16.03 | 8.50 |
Bearish
2
Neutral
5
Bullish
7
Bearish
21
Neutral
5
Bullish
20
Bearish
19
Neutral
0
Bullish
13
Beta Drugs Limited is primarily engaged in manufacturing and marketing oncology drug products, catering to both domestic and international markets.
The company experienced a 13% revenue growth year-over-year, with notable expansions into 46+ countries, showcasing its extensive global reach and market acceptance.
Beta Drugs Limited acquired an oncology intermediate facility to enhance backward integration, reducing dependency on imports and improving margins.
Its entry into the cosmeceutical market through an exclusive agreement with Promoitalia marks a strategic diversification, enhancing their product offerings in high-end derma fillers.
The company is positioned for growth, focusing on developing in-house API capabilities and expanding its CDMO business, reflecting strategic investments in R&D and production capacities.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,342 Cr
Low Risk
33.2
32.3
12.3
5.9
2,000.00
990.10
Sales CAGR
Profit CAGR
ROE
ROCE
